Brokers Set Expectations for Hikma Pharmaceuticals Plc’s FY2017 Earnings (HKMPF)

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF) – Jefferies Group decreased their FY2017 earnings per share estimates for shares of Hikma Pharmaceuticals in a report released on Monday. Jefferies Group analyst J. Vane-Tempest now forecasts that the company will earn $0.88 per share for the year, down from their previous estimate of $0.92. Jefferies Group currently has a “Hold” rating on the stock. Jefferies Group also issued estimates for Hikma Pharmaceuticals’ FY2018 earnings at $0.81 EPS, FY2019 earnings at $0.85 EPS, FY2020 earnings at $0.96 EPS and FY2021 earnings at $1.03 EPS.

Other analysts also recently issued research reports about the company. Morgan Stanley reissued an “equal weight” rating on shares of Hikma Pharmaceuticals in a research note on Tuesday, August 8th. Zacks Investment Research raised Hikma Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 31st. Finally, Goldman Sachs Group downgraded Hikma Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 22nd. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. The company presently has an average rating of “Hold”.

Shares of Hikma Pharmaceuticals (OTCMKTS:HKMPF) opened at $13.60 on Tuesday. Hikma Pharmaceuticals has a 12 month low of $12.40 and a 12 month high of $27.50.

TRADEMARK VIOLATION NOTICE: “Brokers Set Expectations for Hikma Pharmaceuticals Plc’s FY2017 Earnings (HKMPF)” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply